Infectious Complications with Respiratory Pathogens despite Ciprofloxacin Therapy
To the Editor: Ciprofloxacin, a fluoroquinolone, is widely used for a broad range of infections. 1 Although it has had some success in treating respiratory tract infections, delayed clinical responses and the failure to eradicate pathogens from sputum have been reported in some patients with Strepto...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 1991-08, Vol.325 (7), p.520-521 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 521 |
|---|---|
| container_issue | 7 |
| container_start_page | 520 |
| container_title | The New England journal of medicine |
| container_volume | 325 |
| creator | Lee, B L Padula, A M Kimbrough, R C Jones, S R Chaisson, R E Mills, J Sande, M A |
| description | To the Editor:
Ciprofloxacin, a fluoroquinolone, is widely used for a broad range of infections.
1
Although it has had some success in treating respiratory tract infections, delayed clinical responses and the failure to eradicate pathogens from sputum have been reported in some patients with
Streptococcus pneumoniae
2
In addition, its in vitro activity against gram-positive cocci is marginal.
1
,
3
Minimal inhibitory concentrations for S.
pneumoniae
and group A streptococcus range from 1 to 4 μg per milliliter, whereas the maximal serum level achieved after a 500-mg oral dose is approximately 2.5 μg per milliliter.
4
We report here the cases of six patients . . . |
| doi_str_mv | 10.1056/NEJM199108153250719 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80691049</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>80691049</sourcerecordid><originalsourceid>FETCH-LOGICAL-c336t-83674570fcaa395469d3cc4dc3ac429d78b1f246136fd1628bb3577103b6f1d63</originalsourceid><addsrcrecordid>eNp9UMtOwzAQtBColMIXIKScuKCAN3ac-IiiForKU-UcOY5NXeWFnQr697hKJS6Ivexjdka7g9A54GvAMbt5mj48AueAU4hJFOME-AEa-5qElGJ2iMYYR2lIE06O0Ylza-wDKB-hEaRxBByP0eu80Ur2pt24IGvrrjJS-K5xwZfpV8Gbcp2xom_tNngR_ar9UB4qd9NeBZnpbKur9ltI0wTLlbKi256iIy0qp872eYLeZ9Nldh8unu_m2e0ilISwPkwJS2icYC2FIDymjJdESlpKIiSNeJmkBeiIMiBMl8CitChInCSAScE0lIxM0OWg62_43CjX57VxUlWVaJT_Jk8x89ZQ7hfJsCht65xVOu-sqYXd5oDznZH5H0Z61sVeflPUqvzlDM55_GrA69rljVrX_6r9AMlHes0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80691049</pqid></control><display><type>article</type><title>Infectious Complications with Respiratory Pathogens despite Ciprofloxacin Therapy</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Lee, B L ; Padula, A M ; Kimbrough, R C ; Jones, S R ; Chaisson, R E ; Mills, J ; Sande, M A</creator><creatorcontrib>Lee, B L ; Padula, A M ; Kimbrough, R C ; Jones, S R ; Chaisson, R E ; Mills, J ; Sande, M A</creatorcontrib><description>To the Editor:
Ciprofloxacin, a fluoroquinolone, is widely used for a broad range of infections.
1
Although it has had some success in treating respiratory tract infections, delayed clinical responses and the failure to eradicate pathogens from sputum have been reported in some patients with
Streptococcus pneumoniae
2
In addition, its in vitro activity against gram-positive cocci is marginal.
1
,
3
Minimal inhibitory concentrations for S.
pneumoniae
and group A streptococcus range from 1 to 4 μg per milliliter, whereas the maximal serum level achieved after a 500-mg oral dose is approximately 2.5 μg per milliliter.
4
We report here the cases of six patients . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJM199108153250719</identifier><identifier>PMID: 1852190</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Adult ; Aged ; Bacterial Infections - drug therapy ; Ciprofloxacin - therapeutic use ; Drug Resistance, Microbial ; Female ; Humans ; Male ; Middle Aged ; Respiratory Tract Infections - drug therapy</subject><ispartof>The New England journal of medicine, 1991-08, Vol.325 (7), p.520-521</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c336t-83674570fcaa395469d3cc4dc3ac429d78b1f246136fd1628bb3577103b6f1d63</citedby><cites>FETCH-LOGICAL-c336t-83674570fcaa395469d3cc4dc3ac429d78b1f246136fd1628bb3577103b6f1d63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJM199108153250719$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJM199108153250719$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,778,782,2748,2749,26090,27911,27912,52369,54051,64372</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1852190$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, B L</creatorcontrib><creatorcontrib>Padula, A M</creatorcontrib><creatorcontrib>Kimbrough, R C</creatorcontrib><creatorcontrib>Jones, S R</creatorcontrib><creatorcontrib>Chaisson, R E</creatorcontrib><creatorcontrib>Mills, J</creatorcontrib><creatorcontrib>Sande, M A</creatorcontrib><title>Infectious Complications with Respiratory Pathogens despite Ciprofloxacin Therapy</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>To the Editor:
Ciprofloxacin, a fluoroquinolone, is widely used for a broad range of infections.
1
Although it has had some success in treating respiratory tract infections, delayed clinical responses and the failure to eradicate pathogens from sputum have been reported in some patients with
Streptococcus pneumoniae
2
In addition, its in vitro activity against gram-positive cocci is marginal.
1
,
3
Minimal inhibitory concentrations for S.
pneumoniae
and group A streptococcus range from 1 to 4 μg per milliliter, whereas the maximal serum level achieved after a 500-mg oral dose is approximately 2.5 μg per milliliter.
4
We report here the cases of six patients . . .</description><subject>Adult</subject><subject>Aged</subject><subject>Bacterial Infections - drug therapy</subject><subject>Ciprofloxacin - therapeutic use</subject><subject>Drug Resistance, Microbial</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Respiratory Tract Infections - drug therapy</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UMtOwzAQtBColMIXIKScuKCAN3ac-IiiForKU-UcOY5NXeWFnQr697hKJS6Ivexjdka7g9A54GvAMbt5mj48AueAU4hJFOME-AEa-5qElGJ2iMYYR2lIE06O0Ylza-wDKB-hEaRxBByP0eu80Ur2pt24IGvrrjJS-K5xwZfpV8Gbcp2xom_tNngR_ar9UB4qd9NeBZnpbKur9ltI0wTLlbKi256iIy0qp872eYLeZ9Nldh8unu_m2e0ilISwPkwJS2icYC2FIDymjJdESlpKIiSNeJmkBeiIMiBMl8CitChInCSAScE0lIxM0OWg62_43CjX57VxUlWVaJT_Jk8x89ZQ7hfJsCht65xVOu-sqYXd5oDznZH5H0Z61sVeflPUqvzlDM55_GrA69rljVrX_6r9AMlHes0</recordid><startdate>19910815</startdate><enddate>19910815</enddate><creator>Lee, B L</creator><creator>Padula, A M</creator><creator>Kimbrough, R C</creator><creator>Jones, S R</creator><creator>Chaisson, R E</creator><creator>Mills, J</creator><creator>Sande, M A</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19910815</creationdate><title>Infectious Complications with Respiratory Pathogens despite Ciprofloxacin Therapy</title><author>Lee, B L ; Padula, A M ; Kimbrough, R C ; Jones, S R ; Chaisson, R E ; Mills, J ; Sande, M A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c336t-83674570fcaa395469d3cc4dc3ac429d78b1f246136fd1628bb3577103b6f1d63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Bacterial Infections - drug therapy</topic><topic>Ciprofloxacin - therapeutic use</topic><topic>Drug Resistance, Microbial</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Respiratory Tract Infections - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, B L</creatorcontrib><creatorcontrib>Padula, A M</creatorcontrib><creatorcontrib>Kimbrough, R C</creatorcontrib><creatorcontrib>Jones, S R</creatorcontrib><creatorcontrib>Chaisson, R E</creatorcontrib><creatorcontrib>Mills, J</creatorcontrib><creatorcontrib>Sande, M A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, B L</au><au>Padula, A M</au><au>Kimbrough, R C</au><au>Jones, S R</au><au>Chaisson, R E</au><au>Mills, J</au><au>Sande, M A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Infectious Complications with Respiratory Pathogens despite Ciprofloxacin Therapy</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>1991-08-15</date><risdate>1991</risdate><volume>325</volume><issue>7</issue><spage>520</spage><epage>521</epage><pages>520-521</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>To the Editor:
Ciprofloxacin, a fluoroquinolone, is widely used for a broad range of infections.
1
Although it has had some success in treating respiratory tract infections, delayed clinical responses and the failure to eradicate pathogens from sputum have been reported in some patients with
Streptococcus pneumoniae
2
In addition, its in vitro activity against gram-positive cocci is marginal.
1
,
3
Minimal inhibitory concentrations for S.
pneumoniae
and group A streptococcus range from 1 to 4 μg per milliliter, whereas the maximal serum level achieved after a 500-mg oral dose is approximately 2.5 μg per milliliter.
4
We report here the cases of six patients . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>1852190</pmid><doi>10.1056/NEJM199108153250719</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 1991-08, Vol.325 (7), p.520-521 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80691049 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Adult Aged Bacterial Infections - drug therapy Ciprofloxacin - therapeutic use Drug Resistance, Microbial Female Humans Male Middle Aged Respiratory Tract Infections - drug therapy |
| title | Infectious Complications with Respiratory Pathogens despite Ciprofloxacin Therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T04%3A13%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Infectious%20Complications%20with%20Respiratory%20Pathogens%20despite%20Ciprofloxacin%20Therapy&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Lee,%20B%20L&rft.date=1991-08-15&rft.volume=325&rft.issue=7&rft.spage=520&rft.epage=521&rft.pages=520-521&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJM199108153250719&rft_dat=%3Cproquest_cross%3E80691049%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80691049&rft_id=info:pmid/1852190&rfr_iscdi=true |